Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frontier5 open-label safety study of Mim8 in haemophilia A patients switching from emicizumab
jRCT2051230112Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Primary safety endpoint. Started Nov 2023; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2051230112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230112.